Data from Clinicaltrials.gov - Curated by EPG Health - Last updated 02 April 2019
To evaluate the effect of erenumab compared to placebo on the change from baseline in monthly migraine days, in adults with episodic migraine.
Adults with a history of migraine with or without aura for ≥ 12 months and who experience ≥ 4 to < 15 migraine days per month with < 15 headache days per month will be randomized 1:1 to placebo or erenumab. Double-blind erenumab or placebo will be administered during the 12-week double-blind treatment phase and open-label erenumab will be administered during the 28-week open-label treatment phase.
Study Type: Interventional (Clinical Trial)
Actual Enrollment: 577 participants
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention
Actual Study Start Date: July 19, 2015
Actual Primary Completion Date: July 11, 2016
Actual Study Completion Date: March 20, 2017
- Placebo Comparator: Placebo
- Experimental: Erenumab
- ARISE: A Phase 3 randomized trial of erenumab for episodic migraine.
|Date last updated at source||08-Aug-18|
|Study start date||19-Jul-15|
|Estimated primary completion date||11-Jul-16|